1 |
Martin GS. Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes [J]. Expert Rev Anti-Infect Ther, 2012,10(6):701~706.
|
2 |
Martin G, brunkhorst fm, janes jm, et al. the international progress registry of patients with severe sepsis: drotrecogin alfa (activated) use and patients outcomes [J]. Crit Care, 2009, 3(3):R103.
|
3 |
Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference [J]. Intensive Care Med, 2003,29(4):530-538.
|
4 |
Deutschman CS, Tracey KJ. Sepsis: current dogma and new perspectives [J]. Immunity, 2014,40(4):463-475.
|
5 |
Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach [J]. Lancet Infect Dis, 2013,13(3):260-268.
|
6 |
Dellinger RP. Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012[J]. Intensive Care Med, 2013,39(2):165-228.
|
7 |
Pierrakos C, Vincent JL. Sepsis biomarkers: a review [J]. Crit Care, 2010,14(1):R15.
|
8 |
Haran JP, Beaudoin FL, Suner S, et al. C-reactive Protein as predictor of bacterial infection among patients with an influenza-like illness [J]. Am J Emerg Med, 2013,31(1):137-144.
|
9 |
Pradhan S, Ghimire A, Bhattarai B, et al. The role of C-reactive protein as a diagnostic predictor of sepsis in a multidisciplinary Intensive Care Unit of a tertiary care center in Nepal[J]. Indian J Crit Care Med, 2016, 20(7):417-20.
|
10 |
Poddar B, Gurjar M, Singh S, et al. Reduction in procalcitonin level and outcome in critically ill children with severe sepsis/septic shock-A pilot study [J]. J Crit Care, 2016,12(36):230-233.
|
11 |
Schuetz P, Albrich W, Christ-Crain M, el al. Procalcitonin for guidance of antibiotic therapy [J]. Expert rev Anti Infect Therapy, 2010,8(5):575-587.
|
12 |
Schulte W, Bernhagen J, Bucala R. Cytokines in sepsis: potent immunoregulators and Potential Therapeutic targets-an updated view [J]. Mediat Inflamm, 2013:165974.
|
13 |
Mierzchala M, Krzystek-Korpacka M, Gamian A, et al. Quantitative indices of dynamics in concentrations of lipopolysaccharide-binding protein (LBP) as prognostic factors in severe sepsis/septic shock patients-comparison with CRP and Procalcitonin [J]. Clin Biochem, 2011,44(5-6):357-363.
|
14 |
Elwady S, Botros SK, Sorour AE, et al. neutrophil CD64 as a diagnostic marker of sepsis in neonates [J]. J Investig Med, 2014, 62(3):644-649.
|
15 |
Iba T, Gando S, Murata A, et al. Predicting the severity of systemic inflammatory response syndrome(SIRDS)-associate coagulopathy with hemostatic molecular markers and vascular endothelial injury markers [J]. J Trauma, 2007,63(5):1093-1098.
|
16 |
Shozushima T, Takahashi G, Matsumoto N, et al. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome [J]. J Infect Chemother, 2011, 17(6):764-769.
|
17 |
Endo S, Suzuld Y, Takahashi G, et al. presepsim as a powerful monitoring tool for the Prognosis and treatmet of sepsis:a multicenter prospective study [J]. J Infect Chemother, 2014,20(1):30-34.
|
18 |
Cao Z, Robinson AS. The role of Proteomic in understanding biological mechanism of sepsis [J]. Proteomics Clin Appl, 2014,8(1-2):35-52.
|